Bristol Myers Squibb (CELG-RI) Revenue (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Revenue of $13.0 billion for Q2 2026, up 5.74% year-over-year from $12.3 billion in Q2 2025, and up 12.92% quarter-over-quarter from $11.5 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Revenue (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Revenue for 18 consecutive years, with $13.0 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Revenue rose 5.74% year-over-year to $13.0 billion; the TTM figure through Jun 2026 stood at $49.2 billion (up 3.11% YoY), while the FY2025 annual figure was $48.2 billion, changed 0.22% from the prior year.
- Revenue improved to $13.0 billion in Q2 2026 per CELG-RI's latest filing, from $11.5 billion in the prior quarter.
- Across five years, Revenue topped out at $13.0 billion in Q2 2026 and bottomed at $11.0 billion in Q3 2023.
- Historically, Revenue has averaged $11.8 billion across 5 years, with a median of $11.8 billion in 2022.
- Annual changes were most pronounced in 2024 — Revenue advanced 8.69% — and 2025, when it fell 5.6%.
- Bristol Myers Squibb's Revenue stood at $11.4 billion in 2022, then climbed by 0.62% to $11.5 billion in 2023, then climbed by 7.54% to $12.3 billion in 2024, then rose by 1.3% to $12.5 billion in 2025, then grew by 3.77% to $13.0 billion in 2026.
- Business Quant data shows CELG-RI's Revenue at $13.0 billion in Q2 2026, $11.5 billion in Q1 2026, and $12.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 25.31 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 16.99 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 16.61 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 14.41 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 15.38 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 10.05 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 7.80 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 15.03 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.28 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 12.97 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.97 Bn |
| Mar 31, 2026 | 11.49 Bn |
| Dec 31, 2025 | 12.50 Bn |
| Sep 30, 2025 | 12.22 Bn |
| Jun 30, 2025 | 12.27 Bn |
| Mar 31, 2025 | 11.20 Bn |
| Dec 31, 2024 | 12.34 Bn |
| Sep 30, 2024 | 11.89 Bn |
| Jun 30, 2024 | 12.20 Bn |
| Mar 31, 2024 | 11.87 Bn |
| Dec 31, 2023 | 11.48 Bn |
| Sep 30, 2023 | 10.97 Bn |
| Jun 30, 2023 | 11.23 Bn |
| Mar 31, 2023 | 11.34 Bn |
| Dec 31, 2022 | 11.41 Bn |
| Sep 30, 2022 | 11.22 Bn |
| Jun 30, 2022 | 11.89 Bn |
| Mar 31, 2022 | 11.65 Bn |
| Dec 31, 2021 | 11.99 Bn |
| Sep 30, 2021 | 11.62 Bn |